Status:
COMPLETED
Modified-FOLFIRINOX Regimen Based Neoadjuvant Therapy in Chinese Patients With Locally Advanced Pancreatic Cancer
Lead Sponsor:
Second Affiliated Hospital, School of Medicine, Zhejiang University
Conditions:
Pancreatic Cancer
Chemotherapy Effect
Eligibility:
All Genders
18-85 years
Brief Summary
FOLFIRINOX regimen is first-line neoadjuvant chemotherapies for patients with locally advanced pancreatic cancer (LAPC) worldwide. However, FOLFIRINOX is not well accepted in China because of the high...
Detailed Description
At this institution, a mFOLFIRINOX regimen has been adopted for metastatic pancreatic cancer (MPC) patients and promising results obtained. The modification resulted in a significantly reduced prevale...
Eligibility Criteria
Inclusion
- The patients are diagnosed by histology to have pancreatic adenocarcinoma
- The patients are defined as locally advanced pancreatic cancer according to NCCN guideline
- The patients prescribed mFOLFIRINOX-based neoadjuvant therapy
Exclusion
- ECOG performance score more than 2
- Insufficient bone marrow, liver and renal function
- Patients with other malignancies
- Patients were older than 85 years or less than 18 years
Key Trial Info
Start Date :
April 1 2014
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
November 1 2017
Estimated Enrollment :
41 Patients enrolled
Trial Details
Trial ID
NCT03469375
Start Date
April 1 2014
End Date
November 1 2017
Last Update
March 27 2018
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
the second affiliated hospital of Zhejiang University
Hangzhou, Zhejiang, China, 310009